Accessibility Menu
Acurx Pharmaceuticals logo

Acurx Pharmaceuticals(NASDAQ) ACXP

Market Cap$6.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year-78%
1 Month-6%
$1.37
-1.44%
-0.02Today
Acurx Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.442026-07-31
Acurx Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.41%USD 1.422026-07-24
1 month-5.88%USD 1.532026-07-01
3 month-33.33%USD 2.162026-05-01
Year to date-42.17%USD 2.492025-12-31
1 year-77.91%USD 6.522025-07-31
3 year-96.36%USD 39.602023-08-01
5 year-98.73%USD 113.602021-07-30
Since inception-99.09%USD 157.802021-06-25

Acurx Pharmaceuticals Financials at a Glance

Market Cap

$6.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.50M

EPS (TTM)

-$4.40

P/E Ratio

-0.33

Dividend

$0.00

Beta (Volatility)

0.76 (Low)

Price

$1.37

Volume

27,410.013

Open

$1.44

Previous Close

$1.44

Daily Range

$1.38 - $1.44

52-Week Range

$1.33 - $8.34

Estimated Earnings Date

Aug 14, 2026

ACXP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acurx Pharmaceuticals

Acurx develops new antibiotics for hard-to-treat bacterial infections. Its main products aim to help patients with serious gut and hospital-acquired infections. These medicines target bacteria that are resistant to common treatments.

What’s in the Medicine Cabinet?

  • Ibezapolstat: Antibiotic for Clostridioides difficile infections, a severe gut infection; no revenue yet.
  • ACX-375C: Early-stage antibiotic for drug-resistant bacteria like MRSA; no revenue yet.
  • Research and Development: Focused on new antibiotics for hospital and community infections; R&D is a primary area of spending.

Growth and Expansion: The Acurx Adventure

  • Completed Phase II trial for ibezapolstat in 2025.
  • Secured equity line of credit with Lincoln Park Capital Fund in May 2025.
  • Raised $2.1 million and $0.9 million in direct offerings in January and March 2025.
  • Raised $2.5 million through a warrant inducement agreement in June 2025.
  • Completed a 1-for-20 reverse stock split in August 2025.

What Makes Acurx a Bit Different?

Acurx targets bacteria that resist most antibiotics, focusing on new ways to fight infection. Its lead drug uses a unique approach, blocking a bacterial enzyme not targeted by other drugs. The company relies on partnerships and outside vendors for research and development.

Five Things You Need to Know

  • No revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $-2.2 million in Q2 2025, down 46% from Q2 2024.
  • Cash was $6.1 million as of June 30, 2025, up from $3.7 million at year-end 2024.
  • Operating expenses fell 45% year-over-year in Q2 2025.
  • Ongoing risk of NASDAQ delisting and need for more funding to continue operations.

Bottom Line

Acurx is a small biotech focused on new antibiotics for resistant infections. The company remains pre-revenue and depends on outside funding to advance its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

David P. Luci, CPA

Website

www.acurxpharma.com

Headquarters

Staten Island, NY 10305, US

ACXP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-153.93%

Return on Capital

-153.59%

Return on Assets

-78.60%

Earnings Yield

-3.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.30M

Volume

27.41K

Avg. Volume

94.01K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.63M

EBITDA

-$7.50M

Operating Cash Flow

-$6.14M

Capital Expenditure

$3.00

Free Cash Flow

-$6.14M

Cash & ST Invst.

$9.25M

Total Debt

$0.00

Acurx Pharmaceuticals Performance Analysis

Acurx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Acurx Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Acurx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -22.36-10.4%
20232023-12-31USD -23.012.9%
20242024-12-31USD -17.45-24.2%
20252025-12-31USD -5.32-69.5%
Acurx Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.7%
Q32025-09-3034.9%
Q42025-12-3145.5%
Q12026-03-31-67.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$6.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.55M

N/A

Employees

4

N/A

Net Income

-$1.68M

+21.8%

EBITDA

-$1.68M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$9.25M

+99.3%

Total Debt

$0.00

N/A

Accounts Receivable

$56.31K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-78.60%

N/A

Return on Invested Capital

-1.09%

N/A

Free Cash Flow

-$1.41M

+31.4%

Operating Cash Flow

-$1.41M

+31.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCDABioCardia, Inc.
$0.82+6.89%
APREAprea Therapeutics, Inc.
$0.62-2.36%
APVOAptevo Therapeutics Inc.
$4.11-0.48%
ADILAdial Pharmaceuticals, Inc.
$3.34+1.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About ACXP

What is the current price of Acurx Pharmaceuticals?

Acurx Pharmaceuticals is trading at $1.44 per share.

What is the 52-week range for Acurx Pharmaceuticals?

Over the past 52 weeks, Acurx Pharmaceuticals has traded between $1.33 and $8.34.

How much debt does Acurx Pharmaceuticals have?

As of the most recent reporting period, Acurx Pharmaceuticals reported total debt of $0.00.

How much cash does Acurx Pharmaceuticals have on hand?

Acurx Pharmaceuticals reported $9.25M in cash and cash equivalents in its most recent financial results.

What is Acurx Pharmaceuticals’s dividend yield?

Acurx Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services